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Executive Summary 
 
1. For forty years the Misuse of Drugs Act 1971 has formed the corner stone of drug policy in 
Britain.  The emergence of new psychoactive substances (‘legal highs’) during the past fifteen 
years or so has challenged the drug control system. The arrival in 2012 of a new psychoactive 
substance on the market, on average, every six days raises questions about how best to protect 
young people from unknown and unsafe drugs.  The Government is considering this challenge 
and we hope this Inquiry report will make a helpful contribution to their deliberations. 
2. Two research officers have worked with a panel of nine members of the All Party Parliamentary 
Group on Drug Policy Reform to undertake the Inquiry and produce this report.  We have 
examined the literature, considered the initiatives of other Countries to deal with new 
psychoactive substances (NPS) and have had the benefit of evidence from more than thirty 
organisations, including ACPO,  ACMD and other government bodies, professional associations, 
and  experts. 
3. The focus of this Inquiry has been new psychoactive substances.  However, the legal framework 
for traditional drugs and its consequences profoundly affects the use of new substances. Our 
witnesses repeatedly referred across to the impact of the traditional drug market upon the 
demand for NPS.  For example, because ecstasy is a controlled substance, young people obtain it 
from illegal drug dealers who often mix it with dangerous substances.   During periods when 
ecstasy is particularly contaminated, young people turn to a new psychoactive drug which 
mimics ecstasy.  If government wants to reduce the use of NPS, any policy must take account of 
the interaction between the markets for traditional and ‘new’ drugs.  
4. The All-Party Parliamentary Group is mindful that psychoactive substances can be very harmful 
particularly to young people who are also the age group most likely to be involved with drugs.  
5. If we are to minimise the harms, appropriate controls are necessary. A clear conclusion from this 
work, however, has been that banning drug use does not materially affect the overall level of 
demand for drugs. Drug policies which criminalise young people generate higher levels of 
unemployment, homelessness and relationship problems, and cost the taxpayer considerable 
sums.   
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Temporary Class Drug Orders (TCDO) for New Psychoactive Substances 
6. We begin our analysis by considering the effectiveness of the current system for regulating new 
psychoactive substances.   The Police and Social Responsibility Act introduced Temporary Class 
Drug Orders in 2011.  The supply of a new psychoactive substance may be banned for up to a 
year while a risk assessment is undertaken by the Advisory Council on the Misuse of Drugs.  At 
the end of the 12 month period the substance may cease to be banned or will carry the full 
weight of a permanent ban, covering possession, use and supply. 
7. The Inquiry welcomes the fact the Temporary Class Drug Orders do not criminalise users of the 
banned substance during the one year period.  This is the first time since 1971 that any 
government has banned the supply of a drug while not criminalising possession and use.  
However, the evidence makes clear that the current legislative framework, while not 
criminalising users, which is welcome, does not protect them.   
8. The greatest risk to young people from new psychoactive substances derives from the absence 
of reliable information about the contents and strength of each new substance and its effects 
both short and long term.   The name of the substance may tell a user little about its contents, 
and the contents may change from week to week.   The more substances are banned the more 
are created and the greater the uncertainties for consumers.  Over time consumers will be 
criminalised for using these drugs as the Temporary Class Drug Orders expire and the full 
provisions of the Misuse of Drugs  Act apply.  We anticipate that, due to the paucity of 
information available, rarely if ever will a ban be lifted. 
9. A harm-based drug policy demands that the Orders need to stand for sufficient time to enable a 
comprehensive risk assessment to be undertaken.   Also the benefits of avoiding criminalising 
young people should be extended beyond the 12 month period. 
Recommendation 
10. Temporary Class Drug Orders should be of indefinite duration and should therefore be 
renamed Drug Supply Control Orders.  
The consequences of the current system for classifying drugs. 
We next consider the overall system for the classifying of drugs. 
11. The aim of the 1971 Misuse of Drugs Act, as explained by the Home Secretary at that time, was 
to divide drugs according to their accepted dangers, in the light of current knowledge, and to 
provide for classification changes to be made in the light of new scientific knowledge.   
12. This aspiration has not been fulfilled.   Politicians of any political persuasion are reluctant to 
downgrade the classification of any drug as new evidence emerges which would support such a 
decision.  The result is that relatively less harmful drugs like ecstasy and cannabis are 
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inappropriately classified (class A and class B respectively).   The now well-known paper by four 
eminent scientists (Blakemore et al, 2007) illustrates the lack of correlation between the harms 
of a drug and its classification.   Inevitably, the classification system has therefore fallen into 
disrepute.  This situation has implications for NPS drug use. 
13. Governments and the public have to accept that there are young people who will use drugs 
regardless of the risks involved in doing so.  A very small minority but nonetheless too many of 
these young people are addicted to one or more substances.   The Government’s responsibilities 
are four-fold:  1. to provide accurate information (the classification system is just one part of 
this); 2. to provide proportionate controls over the demand and supply of drugs; 3. to provide 
good preventive programmes; and  4. to provide effective treatment environments. 
14. Currently we have a drugs control regime underpinned by an irrational drugs classification 
system, which is ignored by young people; and a banning process which drives the rising tide of 
new psychoactive substances into this Country. We need to place the ACMD at the heart of a 
new evidence based approach. In order to ensure that the judgements of this scientific authority 
are risk based and not influenced by political considerations, it will be necessary to establish the 
independence of the ACMD from government. Politicians need to be responsible for overarching 
policy but we recommend that they are not involved in day to day decisions concerning the risks 
and therefore the classification of individual drugs. 
Recommendation 
15. That the ACMD become an independent decision making body.  The organisation would 
oversee risk analyses; coordinate the research they need;  and make decisions on a scientific 
basis as to the correct classification for each drug, beginning with new psychoactive 
substances.   Politicians would focus on the political decisions concerning the roles of 
treatment and criminal penalties, and the levels of penalties to be applied. 
Necessary system changes in order better to protect young people 
16. We next consider how effectively the current legal framework protects young people against the 
dangers of drugs.   Witnesses to this Inquiry including ACPO and the ACMD questioned the 
suitability of the current system derived from the Misuse of Drugs Act 1971 to respond to recent 
developments.    They were particularly concerned about the number of new substances 
appearing on the market; the use of the internet to purchase new substances, and the use of 
social media by young people to inform others about the latest substances available.  They 
argued that the current system would not be able effectively to control NPS or to minimise harm 
to young people. 
17. Banning substances within the current system has not, and in our view will not, reduce their use 
overall.   Evidence presented here indicates that, paradoxically, the banning of one drug can 
make the situation worse by stimulating the production of yet more new, unknown and 
potentially dangerous substances. 
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18. It is therefore necessary to consider drugs policy as a whole. Two routes for reform present 
themselves.   
A. Regulation 
19. First, could the supply of drugs presenting a low risk to users be controlled under alternative 
regulatory regimes? 
20. The potential of Trading Standards legislation and other consumer protection measures to 
reduce the risks of NPS is cited by many witnesses to this Inquiry.  A number of other countries 
including Poland and Ireland have extended the scope of consumer protection legislation by 
introducing a broad definition covering all psychoactive substances, not already covered by 
existing laws.   The supply and distribution of NPS are then declared illegal under misuse of drugs 
or product safety legislation. Although these initiatives have the advantage that they tend to 
focus on supply and do not generally criminalise users, they have two of the negative 
consequences of prohibition.  Users committed to using NPS have to engage with illegal 
suppliers and to accept the risks involved. 
21. Trading Standards Services in the UK have a wealth of experience and powers to control 
dangerous or mis-described products sold in the high street or on line.   However, Trading 
Standards legislation would need to be strengthened to deal with new psychoactive substances.  
Appropriate testing facilities including a national testing centre would also be essential.  
22. In examining the framework of regulation in the UK, our Inquiry has learnt much about the 
regulatory regimes which could be usefully deployed to meet the challenges of NPS;  also to 
what extent alternative regulatory regimes might minimise the  harms of using NPS.  We have 
been impressed by recent developments in New Zealand which has made unique progress in 
designing a policy for the regulation of NPS.  They have examined the best available knowledge 
about the harms of particular psychoactive substances.  They encourage suppliers to focus on 
product safety, and restriction of supply to protect vulnerable consumers, particularly young 
people. 
23. By making more readily available less harmful and pure substances, labelled to inform the user 
about the ingredients, risks and strength of the substance, young people would be encouraged 
to avoid the unknown and therefore more dangerous alternatives. 
Recommendation 
24. That the government consider adopting the key features of the New Zealand policy:  
25. that the onus should be on potential suppliers to demonstrate that a psychoactive substance 
has an agreed ‘low risk of harm’ 
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26. that a testing process is designed to establish that a substance has a low risk of harm which 
balances rigour with the need to encourage  suppliers to operate within legal markets 
27. that NPS meeting the criteria for ‘low risk of harm’ are classified within a category ‘D’ allowing 
restricted supply with clear sanctions and enforcement procedures for breaches of those 
restrictions 
28. That the supply of the more dangerous substances, whether existing illicit drugs or NPS, 
should remain banned.  
B. Decriminalisation 
29. The second reform route considered by the Inquiry and commented upon extensively by 
witnesses is the legal framework for the possession and use of small quantities of drugs.   The 
Temporary Class Drug Orders introduced the decriminalisation of possession and use of NPS for 
12 months.  We have argued that for the new substances, the TCDOs should be of indefinite  
duration. 
30. New psychoactive substances are substitutes for similar and possibly less dangerous traditional 
drugs.   The benefits of decriminalisation of possession and use should be extended to 
traditional drugs. 
31. The UK application of the Misuse of Drugs Act 1971 lags behind the drug policies of a number of 
European Countries (such as the Czech Republic, Spain, Estonia and Portugal).     These countries 
have decriminalised the possession and use of small quantities of drugs.   Many other countries 
have never criminalised possession and use of drugs.   The policy has produced positive results in 
terms of employment, family relationships, housing and savings to the taxpayer. 
Decriminalisation has not significantly affected the level of drug use (though a smaller 
proportion of young people in Portugal are problem drug users than in neighbouring Countries). 
32. The possession and use of drugs (including NPS) could be decriminalised without abolishing the 
Misuse of Drugs Act.  This is helpful because the pressure on the legislative timetable could 
create unnecessary delays before primary legislation can introduce this much needed reform.  
Section 5 of The Act does specify general prohibitions on possession and use but the Regulations 
are permissive. Rudi Fortson QC pointed to the fact that Section 5 could be dis-applied 
altogether under Regulations. 
Recommendation:  
33. That  a cross party review of the Misuse of Drugs Act (1971) is carried out, beginning with 
Temporary Dug Control Orders and including proposals for the decriminalisation of  possession 
and use of small quantities of any drug.   
34. Such a review should include the national governance of drug policy and the respective roles 
of the key departments. 
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Prevention 
35. Evidence from many witnesses emphasized the importance of prevention in any future drugs 
policy. There is very little research into substance specific prevention programmes directed at 
NPS.  We have therefore explored the extent to which prevention programmes directed at the 
misuse of a range of substances including alcohol, tobacco and other drugs, might be effectively 
applied to NPS as well.   
36. Most of the trials have been conducted in the USA and have limitations. Nevertheless the 
studies referred to in this report have much to tell us about the potential of preventive 
interventions.  The main findings from all the studies examined are:   
37. that programmes using interactive methods can significantly reduce the use of drugs (including 
tobacco, alcohol and illegal drugs); 
38. that programmes which focus on parents and improve the parenting skills of parents of young 
people at risk can be effective; 
39. that community-based interventions providing activities for young people, with the participation 
of residents, can be effective;  and 
40. that the case for mass media campaigns is less clearly made out, but even if on their own these 
campaigns cannot reduce use, they may enhance the effectiveness of community interventions. 
Recommendations: 
41. Preventive programmes with a strong evidence base should be promoted much more widely 
within schools and the community.  
42. That resources should be made available for robust evaluation in the UK of preventive 
programmes 
The Inquiry also presents the case for the following recommendations: 
 
43. All NPS policies should be evidence based and subject to evaluation. Such evaluations should 
seek to assess systems of regulation in terms of harms particularly harms to young people. A 
useful benchmark, operating within the New Zealand system, is that the harms of any form of 
regulation should  not be greater than the harms of the substance being regulated  
44. Generic and analogue approaches to the banning of NPS are not recommended. Instead, more 
rigorous approaches that account for individual differences between substances are needed.  
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45. Consideration should be given to an enhanced role for Trading Standards Services. The role 
would need to be underpinned by capacity building and resourcing of the service;   a review of 
the supporting technology required for test purchasing and prosecutions (see also 
recommendation on access to technology)  and the right legislative framework. 
46. A review of the effectiveness of current forms of regulation and their potential  for effective 
regulation of NPS should  be undertaken. 
47. All NPS should have their properties and prevalence assessed according to the basic data set 
recommended by the Independent Scientific Committee on Drugs; measures to offset the 
uncertain, but high costs of this research should be considered including the use of networks 
of experts, university departments and pooling of European resources. 
48. Access to technology and experts with the capacity to identify NPS should be available to all 
public services managing NPS use, including health services.   In the case of technology 
addressing internet based sales, access to this technology should be limited to enforcement 
agencies and the most advanced technology may have to be reserved for the most 
problematic internet vendors. Measures to control costs should include the use of networks of 
experts. 
49. That a minimum of £1.5m be made available for a targeted pilot of Club Drug Clinics in ten 
major hot spots across the UK with a duty to train front line A&E and GP staff, as well as treat 
those suffering persistent harms of NPS use. 
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1. Introduction 
‘Our range of Legal Highs provides everything you could possibly need for a great night out, a great 
night in and everything in between, without breaking the law’1 
This quote is from a typical website selling ‘legal highs’. The recent phenomenon of ‘legal highs’ 
which has brought an increasing number of new psychoactive substances onto the market, causing 
widespread concern about potential health risks, has arisen against the backdrop of a long 
established, prohibitionist framework for drug control at UK and UN level.  
1.1 Background 
1.1.1. Policy in the UK and across the world has, for the past 50 years, been substantially driven 
by the UN Drug Conventions of 1961, 1971 and 1988, and here in the UK, the Misuse of 
Drugs Act 1971 reflects the prohibitionist thrust of the Conventions.  Drug  policy in the 
1960s and ‘70s  was informed by a moral position that drug taking is harmful, with a strong 
overlay of moral disapproval.   Little or no evidence existed at that time to indicate 
whether or not the policies adopted would achieve the desired aim of reducing drug use 
and ultimately achieving what former President Bush later described as a ‘drug free world’. 
1.1.2. Far from diminishing over time, the global use of traditional illicit drugs has increased 
dramatically. Over the last 30 years the global illicit supply of opiates increased by over 4 
times from 1000 metric tonnes in 1980 to 4,800 metric tonnes in 20102.   In England, the 
number of dependent heroin users increased from around 5,000 in 1975 to an 
estimated 281,000 in England by 2007.3  The Conventions and the UK Misuse of Drugs Act 
have failed to achieve their objectives.  
1.1.3. There has been increasing recognition of this failure.   The Global Commission on Drug 
Policy issued their widely publicised report ‘War on Drugs’ in June 2011 urging the World 
to recognise that the war on drugs has failed, with devastating consequences for 
individuals and societies across the globe.   A number of Countries have explored and 
evaluated alternative policies. 
1.1.4. In March 2012, the all American Heads of State Summit in Colombia, chaired by President 
Santos and attended by President Obama and other Presidents from the Region, agreed 
that there should be a technical cost benefit analysis of existing drug policies to report in 
January 2013;  and an evaluation of five different scenarios involving drug policies from the 
most prohibitionist to the most health oriented. That work, undertaken under the auspices 
of the Organisation of American States, will report to the Heads of State summit in 
Guatemala City in early June 2013.   
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1.1.5. The emergence of new psychoactive substances (NPS), produced mainly in China, may 
provide a catalyst for change.  Certainly the rate of increase in the numbers of these new 
substances produced, and the use of the web and social media to distribute them raise 
significant questions about whether the current drug policy infrastructure remains fit for 
purpose.  As things stand, NPS represent a substantial risk to young people.  The branding 
and packaging of the drug may tell the user very little about its content or strength.   
1.1.6. As a result, many organisations, clinical experts, drug policy specialists and academics have 
begun to examine the challenges and benefits that alternative regulatory regimes could 
bring to the problem of ‘new psychoactive substances’.  New Zealand was one of the first 
countries to face widespread use of legal highs.  The New Zealand Law Commission 
considered a number of legislative possibilities to assist in limiting the harms caused4. They 
recommended licensing some substances to improve information for users and thus to 
discourage harmful use. Referring to the work in New Zealand, the UK Drug Policy 
Commission and the think tank Demos raised the possibility of a UK system of regulation 
for these substances in their 2011 report ‘Taking Drugs Seriously’5    
1.1.7. These new approaches are underpinned by a more general interest at the international 
level to explore a range of regulatory measures. At the UN Commission for Narcotic Drugs 
held in March 2012, Australia proposed the following resolution. 
1.1.8. “to consider a  wide variety of evidence-based control measures to tackle the emergence of 
new psychoactive substances, including the use of consumer protection legislation 
regarding medicine and legislation regarding hazardous substances.” 
1.1.9. The UN eventually agreed an amended resolution which sought to retain an emphasis on 
prohibition and unfortunately lost the key phrase ‘evidence-based’. Nonetheless, the 
resolution acknowledged the need to consider other forms of regulation. Its final wording 
was:  
1.1.10. “to consider a wide variety of responses, such as temporary and emergency drug control 
measures in response to an imminent threat to public health, the use of consumer 
protection, medicines legislation and hazardous substances legislation, and, where 
appropriate, to consider criminal justice measures aimed at preventing the illicit 
manufacture and trafficking of new psychoactive substances”.6 
1.1.11. The European Parliament has invited the European Commission to table this year a new 
legislative proposal on new psychoactive substances. 
1.1.12. In the UK there are significant signs that opinions are shifting on drug policy amongst both 
decision makers and the public. A recent UKDPC poll of MPs found that 77% of MPs believe 
UK drug policies are not working.7  A YouGov poll in 2011 found 53% of people rated 
existing policy towards illegal drugs ineffective.8 
1.1.13. The ACMD proposed that the government should encourage the use for drug control of 
European Pharmaceutical Directives, Unfair Trading Regulations, General Product Safety 
Regulations, Advertising Standards and education for consumers as well as a modification 
of the Misuse of Drugs Act.9   
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1.1.14. In the UK there are well established regulatory systems applied to the production and 
supply of alcohol, tobacco, foodstuffs and medicines. Such regulations are designed to 
protect consumers and maintain product standards. The Inquiry examines the potential of 
the existing control framework and of alternative regulatory systems to provide effective 
controls of NPS and thus to protect young people. 
1.2 Conducting the Inquiry 
1.2.1 At its meeting in May 2011 the All-Party Parliamentary Group for Drug Policy Reform 
discussed the recently published report of the UK Drug Policy Commission and the think 
tank Demos Taking Drugs Seriously.  That report argued for new approaches in meeting the 
challenges presented by new psychoactive substances, and for a consideration of 
regulatory mechanisms such as consumer protection and trading standards   Following that 
discussion, the Group agreed to hold an Inquiry to explore the challenges, and if possible to 
make recommendations.   
1.2.2 Terms of Reference for the Inquiry. 
To examine: 
 
 The implications of the increasing rate at which new substances  are coming onto the 
market and the use of the internet and social media; 
 the effectiveness and  long term impacts of the Temporary Class Drug Orders introduced in 
2011; 
 the potential for policy reform at UK and European level following reports from the UK 
Advisory Council for the Misuse of Drugs and the European Monitoring Centre for Drugs 
and Drug Abuse (EMCDDA); 
 the implications of evidence that an increasing number of countries as diverse as Sweden, 
Ireland, The Netherlands and Poland have introduced a range of alternative regulatory 
measures to control ne new psychoactive substances, including medicines, trading 
standards and health and safety legislation.  
I.2.3. After carrying out a study of different regulatory systems and processes in the UK and 
abroad, a targeted call for written evidence was issued in January 2012.  Evidence was 
received from regulatory bodies, other government bodies, professional associations and 
experts. These responses were summarised and emerging themes identified. Key witnesses 
were then invited to give oral evidence at the House of Lords.  APPG members were invited 
to participate in a panel to hear the oral evidence.  Nine members formed the panel and 31 
organisations and experts provided written and/or oral evidence.  (Their names are listed 
on the inside front cover of the report and in appendix two.)  A draft report and the key 
recommendations were discussed at an APPG meeting on 15th October 2012. 
1.2.4. The APPG has had the benefit of the invaluable research expertise and organisational input 
of Dr Jonathan Hurlow, specialist registrar in forensic psychiatry with North London 
Forensic Service, whose services were available to the Inquiry on a voluntary basis.  Frank 
Warburton, research officer to the APPG has also contributed substantially to the  Inquiry 
and to the report. 
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Note on terminology 
1.1.5. In this Inquiry we use the name ‘new psychoactive substance’ rather than the more 
familiar term of ‘legal high’, albeit that we use the term ‘legal highs’ in the title of the 
report because this remains the widely recognised term for such substances.   Some new 
psychoactive substances are now illegal.  (Mephedrone and methoxetamine (‘mexxy’) for 
example).   Many other NPS contain controlled substances and others are likely to become 
controlled in the near future.  ‘Legal high’ therefore no longer accurately describes the new 
synthetic substances which are the subject of this report.   We also recognise that some 
NPS are in fact not new.  However, we believe the term NPS satisfactorily describes the 
chemicals which are the subject of the government’s and our own concern.    
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2. The Challenge 
2.1 The emergence of NPS 
The emerging market for NPS has the following characteristics. 
2.1.1. New substances are emerging onto the market at an increasing rate. According to the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), their early warning 
system logged 24 new substances in 2009, 41 in 2010, 49 in 201110 and 57 by November, 
201211.This rate of increase has been matched by the increase in the number of internet 
based  ‘head shops’. This is understood to have risen from 170 across Europe at the 
beginning of 2010 to 693 at the beginning of this year.12 
2.1.2. The majority (two thirds) of the NPS detected are synthetic cannabinoids and synthetic 
cathinones with synthetic cannabinoids representing the largest single group.13 What is on 
offer from online head shops are natural substances including salvia divinorum14, kratom15 
and hallucinogenic mushrooms16 but also synthetically derived substances as indicated 
above.  
2.1.3 The majority of synthetic substances are produced in China with some being produced in 
India.17 They usually come in the form of 1kg packets of white powder.  
2.1.4 According to the British Crime Survey18,in 2011/12, 3.0% of UK adults had used a Class A 
drug in the previous year – around a million people. Drug use in the UK is described as a 
common if not normal activity. Cannabis was the most commonly used drug in the previous 
year, followed by powder cocaine. ‘Last year’ illicit drug use increased slightly from 8.8% of 
16 to 59 year olds to 8.9%. Although there has been a modest decrease in such use from 
11.1% in 1996, this has been attributed mainly to the decline in the use of cannabis19. It 
cannot be concluded from this that present policies are working since as cannabis use has 
declined, use of new legal highs (many of which do not appear in the BCS) has become 
established. 
2.1.5 Young people (16 to 19 year olds) are the group that is most likely to have taken drugs 
within the last year.20 According to a pan European survey of young people, an average of 
5% of young people had tried a ‘legal high’ However the figure for the UK was  just under 
10%. Other countries reporting high levels of use included Ireland, Latvia and Poland.21 
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Information on the level of use of new psychoactive substances 
2.1.6. Our limited knowledge is based upon a number of sources:   periodic analyses of 
attendances at accident and emergency departments; small local studies and snap shots of 
NPS use;  we have evidence of the prevalence of NPS use in one region of London , for 
example22.  However, the information is scanty, and the results of different studies tend 
not to be consistent.   We know nothing about the long term toxic or health consequences 
of most of the new substances. 
2.1.7. The research evidence presented to the Inquiry suggested that young people turn to NPS 
when drugs such as ecstasy and street cocaine become too contaminated.  A study by 
Sheila Bird indicated that ecstasy and cocaine deaths had been rising sharply in the years 
up to 2007/8 and then decreased by 28% in 2008/9.23At the same time mephedrone use 
was increasing sharply. The author suggests that the two trends are related. Deaths 
associated with the two former drugs fell as young people switched from illegal and 
contaminated ecstasy and cocaine to a substitute (mephedrone).  
2.1.8. The greatest risk posed by NPS is that as one psychoactive substance is banned, another 
springs up, then another and another. Ivory Wave, for example had in it three different 
psychoactive substances over an 18 month period.24 Each new substance may be more 
harmful than the substance it replaces. But more than anything, young people are taking 
substances whose content and strength are unknown to them. The risks of harm/overdose 
must be greater than for well established substances. 
2.1.9. The risk arises from the fact that the name on a drug provides no information about its 
content. The content of Bubble, for example, widely used in the North West, varies from 
one week to the next. Young people assume that Bubble is a single drug. If one week the 
strength is twice as strong as the previous week, or the ingredients are different, the risks 
to the user are obvious.25  
2.1.10. A particular concern relates to synthetic cannabinoids which bind to some of the same 
receptors in the brain more strongly than cultivated cannabis.  It is less clear how long the 
synthetic cannabinoids remain active and even less clear how they may influence the 
relapse rate of serious mental illnesses.26 
2.1.11. Use and prevalence does not appear to be influenced by the legal status of the drug. 
However suppliers are keen to supply non-controlled substances. The grey area between 
controlled substances and ‘legal highs’ is indicated by the results of a testing programme of 
products sold over the internet.27 This revealed that 19% of products contained mixtures 
including controlled substances.  
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2.2 The Current Response 
2.2.1 The UK Government recognises that NPS pose a challenge.   The key features of the UK   
government response are contained within the Action Plan for NPS published in May 
2012.28 Although most of the Action Plan is a presentation of existing work on drugs applied 
to NPS, particular measures include the introduction of Temporary Class Drug Orders, the 
development of a Forensic Early Warning System (FEWs) to track and assess the emergence 
of NPS and the inclusion of NPS within a review of Personal, Social and Health Education 
(PSHE) within schools.  The main challenge is seen in terms of the capacity of the Home 
Office to ban NPS quickly enough. 
2.2.2. The Forensic Early Warning System (FEWS), run by the Home Office’s Centre for Applied 
Science and Technology  has identified  a number of new drugs from samples taken from 
amnesty bins, seizures and test purchases.   The Government, co-ordinating the work of 
multiple agencies, including the UK Border Agency (UKBA) and the Serious and Organised 
Crime Agency (SOCA)), have been successful in identifying the fact that new drugs are 
appearing on the market.29 
2.2.3. From November2011, Temporary Class Drug Orders (TCDO) may be applied to a new 
psychoactive substance. A TCDO is a fast track prohibition of supply and lasts for one year. 
Sanctions of up to 14 years imprisonment and an unlimited fine will apply.   An Order will 
take account of a preliminary assessment by the Advisory Council for the Misuse of Drugs 
(ACMD).  During the ban a further assessment will be undertaken to advise on whether the 
Order should be replaced by permanent control  under the Misuse of Drugs Act (MDA).  
Possession and use of a substance subject to a Temporary Class Drug Order is not 
criminalised during the 12 month period. 
2.2.4. Ketamine, a popular night club drug which causes bladder damage was controlled  under 
the misuse of drugs act in 2006. Methoxetamine is a hallucinogenic NPS with a similar 
chemical make up to Ketamine.  Methoxetamine was marketed as a ‘legal’ and ‘bladder 
friendly’ alternative. Having gathered evidence of use and the serious risks associated with 
it, the ACMD recommended the use of the first Temporary Class Drug Order.30 As a result, 
from April 2012 suppliers can be prosecuted, whilst users cannot.31   
2.2.5 The Government now attempts to keep pace with the introduction of new substances  by 
incorporating them into current legislation on the basis of generic categories. The specific 
chemical compounds of new drugs are listed in the legislation and controlled on the 
grounds that they belong to a family of substances that are controlled.  An example are 
synthetic cannabinoids32. There are hundreds of drugs that meet this description and once 
identified as a synthetic cannabinoid, these drugs can be recommended to be added to this 
family of drugs within the Misuse of Drugs Act. This can be done with a large number of 
drugs at a time. 
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Attempts to control the supply of NPS by other means 
2.2.6. Medicines legislation has been used to a very limited extent to prosecute suppliers of NPS 
where it has been argued that one of the components has been classed as a medicine and 
the sale of the substance contravenes medicine legislation. There have, for example, been 
successful prosecutions for the production of gamma-hydroxy-butyrate (GHB) and l-
benzylpiperazine (GZB) on these grounds.33 
2.2.7.  Trading standards legislation has also been applied to some extent to disrupt the supply of 
NPS using powers with respect to mislabelled products. For example a substance labelled 
bath salts can be defined as a cosmetic and requires a list of ingredients otherwise it can be 
confiscated. A substance labelled plant food can be defined as a fertiliser also requiring a 
list of contents. This is not thought to be a strong enough safeguard by the TSI, however, as 
sellers can choose another description which avoids even this level of regulation. A 
successful prosecution has been brought on these grounds, but proved to be extremely 
expensive and time consuming.   The case involved test purchasing, using expert witnesses 
and a court action.   The result was a very modest fine for the offenders.34 
Responses from other Countries. 
2.2.8 A number of countries from within the EU and elsewhere have amended their legislation to 
disrupt more easily the supply of NPS. These include: Ireland, Sweden, Poland, Hungary  
and Austria. (See appendix 3 for details). Typically, they have adopted a catch all definition 
for a psychoactive substance which circumvents the process of identifying any harms 
associated with individual drugs. They have then applied both drugs legislation and other 
forms of regulation such as product safety legislation to close down suppliers of NPS such 
as head shops. 
2.2.9 New Zealand experimented with the regulation of the party drug Benzylpiperazine (BZP) 
for a number of years until 2008. In 2005 they created a ‘D’ classification whereby it was 
possible that a substance considered to have a low risk of harm could be supplied legally 
but on a restricted basis -for example it was not available to minors and could not be sold 
near schools. On the basis of evidence of moderate harms BZP was scheduled as a 
controlled substance in 2008. Having reviewed this experience the New Zealand Law 
Commission identified two key learning points: - the first that the onus for evidencing low 
risk of harm should be on the supplier not the state and the second that a contributing 
factor to concerns about BZP being legally supplied was a lack of enforcement of those 
regulations restricting its supply. 35 
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3. Towards a safer Response  
3.1 Are Temporary Class Drug Orders the Answer? 
3.1.1 Temporary Class Drug Orders (TCDOs) are the centrepiece of the Government response to 
the rapid growth in the numbers of new psychoactive substances arriving on the market, 
and represent a relatively fast track to eventual control under the Misuse of Drugs Act.  
Although TCDOs do not criminalise users while in force (and this is very welcome), there 
are a number of practical difficulties with them especially in the time and resources 
allocated to a scientific assessment of the potential harms. They drive the supply of new  
drugs underground.  This impedes the task of researching the effects of the substance and 
increases the likelihood that it will decline in quality and purity.  At the end of the 12 
month TCDO period, substances have to date been, and in the future are likely always to 
be, permanently banned, and possession and use become criminalised.  
3.1.2 According to the Home Office TCDOs are intended to limit the supply of a new substance 
while more evidence is gathered about the risks it presents36.  The resources for the ACMD 
are extremely limited.  They only have the capacity to carry out a small number of 
assessments a year (2 or 3 according to the Chairman, Professor Iverson).   The initial 
assessment behind a TCDO can only be superficial and even after a year conclusive data 
about an individual substance is very unlikely to be available. It is important for the Home 
Office to establish harms accurately and to avoid unnecessary bans,  so that legitimate 
research and commercial activities involving the substances are not needlessly impeded 37. 
Representatives of The Independent Scientific Committee on Drugs in giving evidence to 
the Inquiry recommended that a minimum data set38  is populated as a standard 
requirement to inform assessments of harm for each NPS.   
3.1.3 TCDOs are likely themselves to feed the drive for the development of further new 
substances. The first substance to receive a TCDO was methoxetamine ( ‘Mexxy’).   
Methoxetamine was itself developed as a legal alternative to Ketamine which became a 
controlled substance in 2006. One, or more (probably several) alternatives to 
methoxetamine will almost inevitably appear on the market.  Even less will be known 
about the harms caused by those substances.  A useful feature of  New Zealand’s planned 
policy is to assess both the harms arising from a particular substance and the harms arising 
from controlling it. This could form part of the remit of an ACMD assessment. 
3.1.4 One of the Inquiry witnesses hoped that the rapid use of a TCDO may ‘snuff out’ the 
market for new drugs39. But others argued convincingly that this may do little more than 
encourage the proliferation of yet more NPSs that were neither subject to a Temporary 
Class Drug Order nor the Misuse of Drugs act.4041  
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3.1.5 TCDOs are, in essence, an ante-room to full prohibition. No witness could envisage a risk 
assessment which, after 12 months, would lead to the ACMD recommending that the NPS 
in question should not become controlled under the Misuse of Drugs Act.   After this time 
there are no legislative options to regulate NPS  even though these may present a relatively 
low risk of harm to the public. In the absence of other control measures available, the 
ACMD has no alternative but to recommend control under the Misuse of Drugs Act or to 
release the drug onto the market without any regulatory control at all. 
3.1.6 Later we argue that the UK should learn from the developments in New Zealand where a 
process of licensing relatively low risk substances for restricted and regulated supply is 
planned.  If adopted in this country such a process could be linked to an extended period 
for Temporary Class Drug Orders.  At the very least, more time should be made available to 
gather credible evidence on the NPS in line with the requirements of a minimum data set.   
Also there is a need for  more flexibility to enable the testing of alternative approaches to 
regulating new substances  which would avoid the criminalisation of young people who use 
them.  
3.1.7 Recommendation 
Temporary Class Drug Orders should be of indefinite duration and should therefore be       
renamed Drug Supply Control Orders.  
3.2 Risk Based Drug Policy and the Classification System 
3.2.1. The principle that drug policy should be based upon the risks associated with individual 
substances was established by James Callaghan, the Home Secretary responsible for 
introducing the Misuse of Drugs Act 1971.  On 25th March 1970 he explained that: 
“the object here is to make so far as possible, a more sensible differentiation between 
drugs.  It will divide them according to their accepted dangers and harmfulness, in the light 
of current knowledge and it will provide for changes to be made in classification in the light 
of new scientific knowledge”. 42 
In order to fulfil the then Home Secretary’s objective, the classification of drugs must be 
based strictly upon a rigorous analysis of the risks of each drug to the individual and to the 
community. 
3.2.2. Rudi Fortson QC in evidence to the Inquiry took the view that the main problem with 
regard to the misclassification of drugs has been the misuse of the 1971 Misuse of Drugs 
Act.  He argues that aspects of the legislation have become ‘political ‘battlegrounds’ rather 
than being dealt with coherently within the scheme of the Act as a whole’43 The aspirations 
of the then Home Secretary have not been met. 
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Classification system in disrepute – a case for reform 
3.2.3. A paper by four eminent scientists: Professors Colin Blakemore, Leslie King, William 
Saulsbury and David Nutt, published in 2007,  set out to establish a rational classification of 
a range of illicit drugs and five legal drugs of misuse – alcohol, khat, solvents, alkyl nitrites 
and tobacco.44 Their methodology offers a systematic framework and process to assess the 
harms of current and future drugs of abuse. Following their work the ISCD  produced the 
graph below which illustrates the lack of correlation between the harms of a drug and its 
classification, or indeed its legality.45 
                
 
 Figure 1. Substances in order of overall harms divided into harms to users and harms to 
others 
 
3.2.4. Despite this valuable tool for the classification of drugs, political decisions continue to be 
made to classify drugs without apparent regard for the evidence of harm of the different 
substances. The most striking example of a wrongly classified drug is that of ecstasy which 
sits near the bottom of the table of risks/harms, well below alcohol or tobacco, and yet is a 
Class A drug with criminal penalties for use and supply 
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3.2.5 The failure of the classification system to relate penalties to the level of risk involved in 
taking a drug has already led to widespread cynicism about the system.   At present, young 
people are making their own decisions about the safety of particular drugs independent of 
legality or classification.  The aim of the Inquiry is to promote a rational system of controls 
for NPS which would command the respect of young people. 
3.2.6. Some indication of the irrelevance of the current classification system is the fact that the 
UK trend in cannabis use has declined steadily throughout the period in question.46   This 
seems to have occurred independently of the reclassifications of cannabis from class B to C 
and back to B again. The most recent EMCDDA report confirms that cannabis use 
prevalence is far more susceptible to social, cultural and economic factors than drug 
classification.47 The limited relevance of drug policy and classification should liberate 
politicians to take a more relaxed approach to this highly controversial issue. 
3.2.7 Drug use is firmly embedded in our culture particularly amongst young people. The 
purpose of the classification system is surely to give a clear indication to those young  
people who are going to use drugs about the relative harms of  those drugs so that they 
can make informed choices.  The sale of more harmful drugs should accordingly attract 
stiffer penalties. Experts who undertake research and work with experienced club drug 
users, including Dr Owen Bowden-Jones48 and Dr Fiona Measham49are convinced that the 
legal status of a drug has little impact on club goers’ decisions to take NPS. 
3.2.8 Government warnings about the harmfulness of all drugs may be having little effect.50  If 
so, this is a matter for concern.   Young people who take drugs need to be encouraged to 
minimise the harms to themselves and others by their choice of psychoactive substance 
and the way in which they take it.  If they are going to be able to make full use of the 
information from resources like ‘Talk to Frank’ they need to be able to trust the official 
classification system which is meant to differentiate and group drugs on the basis of harms. 
A classification system also needs to enjoy wider public confidence too. 
3.2.9 Dr. Tim Williams and Professor Val Curran suggested that if we can create a rational 
system, users will start to trust it.51 Dr. Williams emphasised the importance of the 
classification system  focusing upon the most harmful drugs.  
3.2.10 Other tools are needed to encourage young people to make informed decisions about 
`drugs, avoid the more serious harms and where possible delay experimentation.  (See 
Section 7 on reducing demand.) 
3.2.11 We recognise that politicians of any political party are apprehensive about proposing 
changes to drug laws which may be perceived as irresponsible or soft and therefore shy 
away from making rational decisions on drug classification in response to evidence. Our 
current drug policy suggests a preference for  a flawed policy rather than appear soft on a 
contentious issue. However, with the growing acceptance amongst MPs and the public that 
current drug laws are not working, and most of the main newspapers supporting a review 
of policy, politicians may want to reconsider their position.  
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3.2.12 In 2006, the House of Commons Science and Technology Committee reviewed the role of 
the ACMD and called for independent oversight of its work including recommendations on 
drug classification.52 In order to ensure that the judgements of this scientific authority are 
risk based and not influenced by political considerations, it will be necessary to establish 
the independence of the ACMD from government. Politicians need to be responsible for 
overarching policy but we recommend that they are not involved in day to day decisions 
concerning individual drugs.    
3.2.13 A newly constituted body would need to have the authority to make classification decisions 
(similar to the independent decisions of the Government’s Monetary Policy Committee 
which determines interest rates, and in the health field, of the National Institute for Health 
and Clinical Excellence which determines those treatments attracting NHS funding). We 
believe this is an essential step in working towards a rational drug policy, and is crucial to 
restoring  the credibility of the government approach and state sponsored information 
campaigns and education programmes. 
Recommendation 
3.2.14. That the ACMD become an independent decision making body.  The organisation would 
oversee risk analyses; coordinate the research they need  and make decisions on a 
scientific basis as to the correct classification for each drug, beginning with new 
psychoactive substances.   Politicians would focus on the political decisions concerning 
the roles of treatment and criminal penalties, and the levels of penalties to be applied. 
 
 
 
3.3 Deciding on Classification – analogue and generic decision 
making  
3.3.1 It has been strongly argued that it is important that the systems of assessment employed 
by an independent body with respect to NPS have credibility. A generic approach to 
classification is in use in the UK. This is based on the assumption that substances which are 
similar in chemical  structure will have similar psychoactive effects and pose similar risks of 
harm. There has also been some interest in the US system of analogue classification53 
which is aimed at groups of substances either similar in chemical make-up or in effect. 
Analogue controls do not require identification of an over arching family of drugs. Instead a 
case must be made that an individual drug is significantly similar to another controlled 
drug. Both generic and analogue approaches can expand the number of drugs managed by 
the current system. Both are based upon a judgement that a particular drug may be  
sufficiently harmful to warrant legislative controls.54 
25 
 
Challenges of the generic and analogue approaches 
3.3.2. Both approaches are attempts to cut short the risk assessment of an NPS to the public by 
assuming the risks of a known drug will apply to a new psychoactive substance. 
Subsequently both approaches have a greater chance of damaging credibility and wasting 
resources by controlling NPS of moderate or low risk to the public. They reduce the 
motivation to acquire high quality risk assessments on specific drug compounds.   This 
approach could lead to dangerous assumptions because small differences between drugs 
can be compatible with significantly different effects on those who take them. For 
example: 
3.3.3. The risks associated with the antipsychotic drug clozapine do not apply to the similarly 
structured drug olanzapine.   Clozapine patients must have regular blood tests due to the 
increased risk that they might develop a potentially fatal side effect, whilst users of  
olanzapine do not carry the same risks  and thus do not need the same frequency of blood 
tests55.  
3.3.4. As far as the analogue approach is concerned, the US Drug Enforcement Agency did not 
recommend it for use in the UK. Their recommendation was a result of court cases arising 
from prosecutions under analogue legislation. These led to significant legal wrangling with 
associated delays and costs. Problems occurred when defendants didn’t  know for certain  
that they had committed an offence until the eventual legal judgment which was likely to 
be long after their arrest;  also serious disputes occurred amongst expert witnesses over 
what constituted a ‘similar structure’ and a ‘similar effect’.56 
Recommendation: 
3.3.5. Generic and analogue approaches to the banning of NPS are not recommended. Instead, 
more rigorous approaches that account for individual differences between substances 
are needed 
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4. Misuse of Drugs Act - Fit for purpose? 
4.1  Struggling to face the challenge of NPS 
4.1.1. The Misuse of Drugs Act 1971 has been in operation for forty years. The focus of the Act  
upon substance misuse as a criminal activity rather than a health problem requiring 
treatment has always been controversial. However, while young people tended to take a 
relatively limited number of established drugs, the 1971 Act appeared to be a viable tool, 
whatever its faults and despite the absence of substantial evidence of effectiveness. Many 
witnesses, however, expressed serious doubts about the feasibility of trying to control New 
Psychoactive Substances using existing powers, particularly given the current limited 
capacity of enforcement agencies. 
According to ACPO:  
 4.1.2.      “the Misuse of Drugs Act 1971 is not well positioned to deal with the more complex drugs 
scene which is now in existence”;  the speed with which new substances are being produced 
and made available; the use of the internet and retail outlets to supply the substances ; and 
the use of social networking to spread news about such substances and to promote their 
use (such as party invitations circulating on smart phones including an internet link to a 
supplier of ‘legal highs’. 
4.1.3. Police operations against large scale importers of NPS are hugely resource intensive, and 
have far from certain outcomes. The financial cost for forensic analysis of all NPS appearing 
on the market, to discover those which need to be controlled, is prohibitive. The 
Association of Chief of Police Officers (ACPO) argues that: 
4.1.4 ”the combination of budget pressure and substantial and ongoing changes to the provision 
of forensic services means that it is most unlikely that unidentified substances such as legal 
highs will be sent off for analysis. The information needed to take action will not be 
routinely available.”57 
4.1.5. The practical implications for police officers on the street at 3.0 am dealing with a young 
person in possession of a substance purchased on the internet, the nature of which they 
themselves are unsure, are self evident. They have no way of knowing the content without 
the availability of accurate field testing devices. Young people can be arrested and placed 
in a cell, interviewed and then bailed pending forensic analysis and released if the 
substance is shown to be legal. This is a waste of Police resources. There is also the 
problem of young people being criminalised for possessing a substance they believed to be 
legal.  
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4.1.6 According to SOCA and the Home Office58 many websites are closed down in response to a 
ban but what is unknown is how many others open up using new names. Despite the best 
efforts of enforcement agencies NPS use is widespread. One in ten young people in the UK 
report having tried an NPS.  The emergence of NPS is exacerbated by an increasing trend 
toward polysubstance use. The ACMD take the view that: 
4.1.7. “Our present system isn’t really designed to cope with it, it’s designed to cope with alcohol 
or heroin or cocaine, one at a time”.59 
4.1.8 Currently,  controlled drugs such as heroin or cocaine are known to be dangerous, but the 
ACMD  points out that the greatest harm may be caused by new substances emerging onto 
the market before there is any knowledge or understanding of their effects. They are 
particularly concerned about under 16’s using NPS.60 
Lack of confidence in current methods of control 
4.1.9. A succession of witnesses to the Inquiry queried the continued use of drug control 
legislation as a solution to the challenge  
ACPO said: - 
4.1.10 “From an early stage the Chair of ACPO Drugs Committee was of the opinion that the 
solution to the particular challenges of legal highs did not lie in adding inexorably to the list 
of illicit substances”. 
Dr John Ramsey added: - 
4.1.11. “paradoxically legislation may make the situation worse as it is the main driver for change 
and the development of yet more new compounds.   As long as large amounts of money can 
be made selling untreated chemicals, for which there is a market of largely young people 
willing to risk using them as drugs, and a chemical industry willing to supply the chemicals, 
the situation is unlikely to improve”. 
Professor Rudi Fortson QC was in agreement: - 
4.1.12 “one cannot be confident that a zero-tolerance approach to psychoactive substances for 
non-medical purposes would not make matters worse.  The experience of the  Misuse of 
Drugs Act 1971 as a social engineering tool is not encouraging”. 
4.1.13 Gus Jaspert from the Home Office acknowledged that it is not known whether when one 
substance is banned, young people move on to a more dangerous but unbanned 
substance.   
Control has no impact on use  
4.1.14. An on line survey of readers of music magazine detected a reduction in use of mephedrone 
from 51% in 2010 to 19.5% in 2011.61  A face to face survey of South London gay clubbers, 
on the other hand, detected an increased in use from 24% in 2010 to 41% in 2011.62 
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4.1.15. Probably the most reliable estimate is that of Dr Simon Elliot, a member of the     
Independent Scientific Committee on Drugs, who said: 
“there was no difference in the number of mephedrone cases in 2011 compared with 2010 
before the ban.” 63 
4.1.16. The main effect of banning mephedrone has been a decrease in the quality of mephedrone  
available64.  
4.1.17. A longitudinal study of ketamine which examined use before and after  the ketamine ban 
was introduced in 2006 shows that the ban made no difference over time to the level of 
use and rather that ketamine use increased significantly in the short term post control65. 
4.1.18. Above are compelling arguments that the current policies are very unlikely to make a 
significant impact on the use of NPS.   However, they have the potential to amplify the risk  
of harms of NPS. Young people need to be able to make informed choices based on risk 
(which may entail a choice of less harmful known substances).  
4.2 Time to  extend the decriminalisation of drug use? 
4.2.1 We found a broad consensus amongst the majority of witnesses, including  regulatory 
authorities, scientists and clinicians in support of the decriminalising of possession and use 
of NPS  under Temporary Class Drug Orders.  The criminalising of users, in this context at 
least,  was regarded as  unhelpful for the individual and for society. 
4.2.2. Looking at the question  from a clinical perspective, Dr. Owen Bowden Jones   argued that 
if someone has an addiction this defines their use and they will use the drug whether it is 
legal or not, regardless of the consequences. This is the nature of addiction. Criminalising 
such people is morally wrong. 
4.2.3 The UK has a strong emphasis upon treatment of addiction. However, our application of 
the Misuse of Drugs Act 1971 lags behind the drug policies of a number of European 
Countries (such as the Czech Republic, Spain, Estonia and Portugal).  These countries have 
decriminalised or depenalised the possession and use of small quantities of drugs.66  
4.2.4. The Portuguese model of decriminalisation of drug possession and use, with its strong 
focus on treatment, has been evaluated. The important finding has been that none of the 
fears of opponents have been realised. The trend in adult use has broadly reflected that in 
neighbouring countries. However, two important positive results are that the numbers of 
young people becoming addicted to drugs has fallen in Portugal under decriminalisation; 
and secondly the number of drug related deaths has fallen. 67  Politicians have nothing to 
fear from this policy.  When the policy was introduced it was challenged by the opposition.  
Today, its drug policy has widespread support within Portugal. 
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4.2.5. While not affecting the level of drug use, drug policies which avoid criminalising young 
people do generate lower levels of unemployment, housing and relationship problems, and 
save the taxpayer considerable sums.  According to the organisation Release, nearly a 
million people in the UK have been convicted or cautioned for drug possession.68 Those 
with a criminal conviction will find it significantly harder to find work.   A report 
commissioned by the Department of Work and Pensions69 indicated that most employers 
would reject candidates with criminal convictions for about half of vacancies. As there is a 
duty to disclose convictions on applications for accommodation and insurance there can be 
a severe impact from a conviction for drug possession. Simply receiving a caution will stay 
on someone’s police record for life. 
4.2.6 If we wait for primary legislation, possession and use of drugs could remain criminalised for 
many years. Pressure on parliamentary time is always a delaying factor in any reform. The 
possession and use of drugs (including NPS) could however, be decriminalised without 
abolishing the Misuse of Drugs Act. The Act does specify general prohibitions but the 
Regulations are permissive. Section 5 of the MDA which makes possession of a controlled 
drug a criminal offence, could be disapplied altogether under Regulations.70 
Recommendation:  
4.2.7 That a cross party review of the Misuse of Drugs Act (1971) is carried out, beginning with 
Temporary Control Drug Orders and including proposals for the decriminalisation of 
possession and use of small quantities of any drug.   
4.2.8 Such a review should include the national governance of drug policy and the respective 
roles of the key departments. 
30 
 
5. New Solutions 
5.1 A focus on Regulation  
5.1.1. We have already documented the widespread interest in various  regulatory regimes as 
possible methods of control of the supply of NPS within the UK and internationally.  One of 
the objectives of our Inquiry has been to explore the potential  of regulation of NPS supply 
and the possibility that one of the existing regulatory regimes may be effective in 
encouraging the use of less harmful drugs and reducing  the many harms arising from 
illegal drug markets.  Trading Standards and Medicines Legislation have already been 
applied in the UK to disrupt the trade in psychoactive substances which are not controlled 
by the Misuse of Drugs Act. But, as indicated below, these applications have been possible 
only in very limited circumstances.  
5.1.2. A number of other countries including Poland and Ireland have extended the scope  of 
consumer protection legislation by introducing a broad definition covering all psychoactive 
substances, not already covered by existing laws.   The supply and distribution of NPS  are 
then declared illegal under misuse of drugs or product safety legislation. Although these 
initiatives have the advantage that they tend to focus on supply and do not generally 
criminalise users, they have two of the negative consequences of prohibition.     Users 
committed to using NPS have to engage with illegal suppliers  and to accept the risks 
involved. (A  summary of initiatives abroad is in Appendix 3.) 
5.1.3. Consumer protection legislation includes a complex array of controls which have 
developed in a  piecemeal fashion to deal with particular challenges.   For example, 
labelling requirements on the contents of many products have been the response to the 
rise in consumer rights.71  There are also specific and distinct regulatory instruments to 
deal with the challenges of currently legal psychoactive substances such as alcohol, 
tobacco and solvents.  None of these regulatory instruments is designed to prevent trading 
in these substances but rather to ensure that the trading takes place under conditions 
designed to achieve safety objectives. 
5.1.4 In examining the frameworks of regulation in the UK, our Inquiry has learnt much about 
the regulatory regimes which could be usefully deployed to meet the challenges of NPS;  
also to what extent alternative regulatory regimes might minimise the  harms of using NPS. 
We have been greatly helped in our deliberations by examining recent developments in 
New Zealand which has made unique progress in designing a policy for the regulation of 
NPS.    They have examined the best available knowledge about the harms of particular 
psychoactive substances.  They encourage suppliers to focus on product safety, and 
restriction of supply to protect vulnerable consumers, particularly young people. 
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5.1.5. Our recommendations call upon the UK government to adopt key features of the New 
Zealand approach.    
Existing Regulation in the UK 
5.1.6 Current forms of regulation apply to a wide variety of products, including food stuffs, 
alcohol, tobacco and solvents. The aim of these regulations is to protect customers and to 
ensure that suppliers and sellers behave responsibly. Other regulations ensure that any 
taxable revenues generated by the above markets accrue to the state. A full list of 
regulatory authorities and mechanisms can be found in Appendix one, but the principal 
ones that may be of relevance to the regulation of new psychoactive substances include:   
 Trading Standards Services (TSS) who enforce many laws and regulations 
including: 
 Consumer Protection from Unfair Trading Regulations 2008; 
 Children and Young Persons (Protection from Tobacco) Act 1991; 
 Criminal Justice and Police Act (2001).  This covers  the sale of alcohol to under 
18s; 
 Intoxicating Substances (Supply) Act 1985 for solvents  (when authorised so to 
do). 
 The Medicines and Health Care Products Regulatory agency (MHRA) which 
regulates medicines in accordance with EU Directive 2001/83/EC and controls the 
sale of medicinal products for human use.  
 HM Revenue and Customs which is responsible for overall taxation and in 
particular, the collection of alcohol and tobacco duties. 
5.1.7. The possible application of advertising standards and premises licensing as currently used 
with respect to the sale of alcohol was also addressed. 
Trading Standards in the UK 
5.1.8 Currently UK Trading Standards are managed and delivered by local government, but work 
to priorities set by National Government or the European Union (EU). The regulations 
include controlling the description and labelling of products and product safety. The former 
is governed by the ‘Consumer Protection from Unfair Trading’ regulations (2008) framed by 
the EU directive – ‘Unfair Commercial Practices’ (adopted in 2005). The latter is governed 
by the General Product Safety Regulations 2005 which follows EU product safety directive 
2001/95/EC. Both directives are harmonised across the EU and any significant changes to 
the way they are implemented would need agreement at EU level.      
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5.1.10 Local authorities are required by law to have trading standards functions under the 
Weights and Measures Act. The areas of responsibility include: fair trading, animal welfare, 
food safety and underage sales. Their activities include: routine inspection, complaint 
investigation, thematic investigation in priority areas, and education. Sanctions include: 
fixed penalty notices, prosecutions, seizures, injunctions, warnings and advice. 
5.1.11. They have experience, powers and skills in the regulatory control of dangerous, unsafe or 
mis-described products, including alcohol, tobacco, solvents, fireworks and poisons among 
others, whether they are sold in high street shops or on-line. 
5.1.12. The role of Trading Standards Services with respect to NPS thus far has focussed on head 
shops and the internet. For head shops there have been a small number of prosecutions 
and also the police and trading standards have reported some local successes in simply 
advising head shops that ‘legal highs’ on sale may contain controlled substances or may 
contain legal but harmful substances.72 However there were doubts within Trading 
Standards as to whether this approach would be replicable across the UK  based on a view  
that  head shops are mis-describing products to such an extent that they are probably 
deliberately operating on the fringes of the law and would not be amenable to advice from 
local Trading Standards officers.73  
5.1.14. There are specific consumer protection laws that apply to internet trading;  for example 
cooling off periods. For the sale of goods at a distance, e-commerce regulations require 
certain information to be included in every transaction.  One of the big difficulties with 
internet trading is the uncertainty about where the site is hosted.  Many are breaking the 
law but are not hosted in the UK and are beyond the remit of local Trading Standards (TS) 
services.74   
5.1.15 Much of the evidence considered by the Inquiry including written and oral evidence from 
witnesses suggested that Trading Standards have an important role in disrupting the supply 
of NPS.75 However a number of conditions would need to be met before TS services could 
have an effective role. The main issues are: - the current capacity of TS services; the 
resources necessary to underpin their work; and the need for reform of the legislative 
framework. 
Capacity  
5.1.16 Trading Standards Services have an important part to play in the regulation of NPS but it 
would not be feasible for the 197 separate TS Services to take on the cost of individual 
investigations into product safety. At present, services are funded by local government and 
they must respond to local priorities.76 
5.1.17 The need to resource and build the capacity of TS services is supported by evidence from 
the Local Government Association (LGA). 77   Further analysis of the potential role of TS 
Services will be needed. 
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Resourcing of support services 
5.1.18 Action on safety with respect to NPS requires testing facilities to establish the potential 
harms and risks. These are generally not available.  Also testing takes time and such 
facilities as exist are not equipped to test for new substances. Several witnesses called for 
the establishment of a national testing centre (See section 6  on essential research). 
The legislation 
5.1.19 Several witnesses referred to the need to adjust the legislative framework for control of 
the supply of NPS.78  The two main areas that could be addressed are legislation with 
respect to consumer protection and to product safety.  
5.1.20 As far as consumer protection is concerned its main purpose currently is to protect the 
economic interest of the consumer79 principally in terms of being misled by the seller. 
However those users of NPS who buy products labelled as ‘bath salts’ from a head shop 
know they are not buying the product as described. So a prosecution would fail because it 
would not be able to establish that the ‘transactional’ decision to buy was based on false 
information.80  This anomaly would need to be addressed if there were to be a wider 
application of consumer protection legislation. 
5.1.21 As far as product safety is concerned, public health concerns such as with alcohol or high 
fat foods sold to minors can be dealt with by national legislation. So another possible 
avenue would be to identify a class of psychoactive products which, on safety grounds,  
could not be sold regardless of how they were marketed or labelled. According to the 
Trading Standards Intitute product safety legislation had been used to good effect in 
improving the labelling of tobacco products. 
5.1.22 Consumer protection and product safety are governed by EU directives.     Strengthening of 
consumer protection would need to be undertaken at EU level.  If this were to take place 
there may be scope to address the requirement for businesses to exercise ‘professional 
diligence’ or to add to the current list of ‘sharp practices’.81 
Recommendation 
5.1.23 Consideration should be given to an enhanced role for Trading Standards Services. The 
role would need to be underpinned by capacity building and resourcing of the service;   a 
review of the supporting technology required for test purchasing and prosecutions (see 
also recommendation on access to technology); and the right legislative framework. 
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Medicines legislation 
5.1.24 The Medicines and Health Care Products Regulatory Agency (MHRA) is the government 
agency responsible for ensuring that medicines and medical devices work, and are 
acceptably safe. The onus is on pharmaceutical companies to demonstrate that a new 
medicine is safe and effective but this process can take 10 to 12 years to bring a new 
medicine onto the market at a cost of £1.1 billion and only one in 5,000 research products 
receives a license.82 
5.1.25. Some witnesses83 argued that the MHRA or medicines legislation could have a wider role 
with respect to NPS but the MHRA have argued that medicines legislation can only be 
applied to products classified as medicines and other witnesses84 have argued against 
broadening its remit. The majority of UK medicines legislation now follows the 
requirements of European legislation, in particular Directive 2001/83/EC, as amended.  
Other countries in the EU have attempted to regulate NPS by classing them as medicines.85  
 
The right legislative framework 
5.1.26 If existing forms of regulation are strengthened as suggested above, within the current 
framework of prohibition, there would still be a number of potential negative 
consequences: 
 banning supply drives NPS to illegal markets with more likely involvement of 
organised crime; 
 the quality and purity of NPS is less assured and the risk of harms to users are 
increased significantly; and 
 differentiation between less harmful NPS and more harmful controlled 
substances may be  more difficult develop. 
5.1.27. Two examples of regulatory instruments that would be unlikely to work under existing 
circumstances but would need to be re-examined within a regulatory framework are 
taxation and the licensing of premises as currently applied to the sale of alcohol. 
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Taxation 
5.1.28 Although the profits and sales of NPS as for any business would be liable to tax, witnesses 
did not think that taxation was a viable way to regulate within the current legal framework 
and that the suppliers of NPS were unlikely to pay tax.86 However figures supplied by the 
Wine and Spirits Trade Association highlighted strongly the revenue lost to the state 
because drugs  are restricted to illegal markets.  Alcohol duty and VAT contributes £16 
billion a year to the public finances.87   If a way could be found to ensure that taxes on NPS 
were paid, this could also be a way of influencing their pricing.  
Licensing of Premises 
5.1.29 Under current legislation, local authorities license individuals and premises to supply 
alcohol with conditions aimed at preventing crime and disorder, protecting public safety, 
preventing public nuisance and protecting children from harm. The licensing of premises 
where NPS are taken can also be considered as a legitimate way of restricting use to 
minimise harms. Witnesses speculated that under current circumstances we could 
anticipate that premises licensed for NPS could increase the population with access to 
those substances, and hence the level and spread of use88.   However venue licensing still 
remains an option to be considered although this approach would need to be tested and 
evaluated.   If premises were licensed to sell specified NPS with conditions, two 
consequences are likely.   Dr Fiona Measham referred to the displacement effect of 
licensed premises for alcohol consumption.   Young people drink in unlicensed premises 
including their own homes.   We could anticipate a similar outcome with NPS.    
5.1.30 The most fully developed example of a drug policy which is trying to address the challenge 
of NPS with regulation is about to become law in New Zealand. 
 
 
 
5.2 New Zealand a case study:  
5.2.1 Several witnesses made reference to the New Zealand policies.89 New Zealand has twice 
attempted to develop systems of regulation for particular NPS.  It first tried by introducing 
a ‘restricted substances’ category within national drugs legislation in 2005. Here a new 
substance could be legally supplied if it was understood to represent a ‘less than moderate 
risk of harm’.90 The restrictions included: - restricted outlets for sale, no sale to minors and 
no advertising.”91 Benzylpiperazine (BZP), was the only substance placed in the restricted 
substance category known as category ‘D’. It was subsequently assessed as having a 
moderate risk of harm and was prohibited in 2008. 
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5.2.2. This first attempt at regulation was not successful but in the face of continued widespread 
use and availability of NPS, New Zealand decided to reconsider regulatory mechanisms. 
5.2.3. In 2010 the New Zealand Law Commission published a comprehensive report on current 
drug policy which recommended consumer protection legislation for all NPS which places 
the onus on producers and suppliers to demonstrate that the substance poses ‘a low risk of 
harm’. The guiding principles behind the recommendation are that drugs should only be 
regulated:-  to prevent harm to the young and otherwise vulnerable who may use the drug 
and to prevent harm to others caused by a person’s drug use;  and only if the benefits of 
regulation outweigh the costs arising from regulation itself.  
5.2.4 They suggested four criteria that could be used to decide whether a substance could be 
legally sold.  
 The nature of the harm caused by the substance (including its prevalence of use) 
and any benefits from its use; 
 whether the harm of the substance can be effectively mitigated by the imposition 
of regulatory controls; 
 likely consequences of any proposed regulation or prohibition of the substance 
(i.e. assessing alternative regulatory approaches) ; and 
 any possible displacement effects that might occur because of the way 
substances are regulated (i.e. the risk that prohibition might encourage the use of 
a more harmful substance)92. 
5.2.5. In response to the report of the Law Commission, The Cabinet of the New Zealand 
Government is proposing a new system of regulation and has undertaken an impact 
assessment of what will be involved. The primary aim of the new system of regulation is to 
‘reduce risks to the public by removing untested and potentially harmful products from 
being sold and introducing a pre-market approval scheme with testing requirements and 
retail restrictions for low-risk psychoactive substances’.93 They anticipate that the number 
of applications will be very small (less than ten) in the first year. 
5.2.6. They propose a process of testing which can establish the potential level of harm with the 
costs met by the supplier. However,  the hurdles that the supplier has to go through cannot 
be so high that they  simply drive the production of NPS into the black market. This point 
was raised in evidence from HMRC who warned that to tax suppliers of NPS at a higher rate 
than current VAT and Income Tax, as is the case with alcohol and tobacco, runs the risk of 
driving the trade into the black market.94    
5.2.7. Currently estimated costs of determining potential risks and harms of NPS are 
approximately half a million pounds and the estimated charge for registration for each 
substance would be nine thousand pounds. In consulting with the potential suppliers the 
New Zealand Government has established that they would generally be prepared to submit 
compounds to be tested and are prepared to pay the costs.95 
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5.2.8 The New Zealand government are clear that regulation is not a soft option and that the 
restrictions applied to the sale of any NPS assessed as low risk will need to be rigorously 
applied. 
Recommendation: 
5.2.9  That the government consider adopting the key features of the New Zealand policy:  
 that the onus should be on potential suppliers to demonstrate that a 
psychoactive substance has an agreed low risk of harm; 
 that a testing process is designed to establish that a substance has a low risk of 
harm which balances rigour with the need to encourage  suppliers to operate 
within legal markets; 
 that NPS meeting the criteria for low risk of harm are classified within a 
category ‘D’ allowing restricted supply with clear sanctions and enforcement 
procedures for breaches of those restrictions; and  
 that the supply of the more dangerous substances, whether existing illicit drugs 
or NPS, should remain banned.  
 
5.2.10 In considering regulation the Inquiry was reminded that there was little evidence of the 
effectiveness of regulation thus far. 
According to Dr Les King, 
5.2.11. “We don't have a lot of evidence of the effectiveness of these other forms of legislation 
because the problem is new, and there's not a great deal of experience but all I can say is 
that they're worth looking at as examples, because clearly the Misuse of Drugs Act isn't 
working now.” 
5.2.12 Accordingly we need to know what works in the current regulatory framework and we 
need to evaluate the impact of any system of regulation for NPS 
Recommendation:  
5.2.13 A review of the effectiveness of current forms of regulation and their potential  for 
effective regulation of NPS should  be undertaken. 
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6. Essential Research 
6.1 Building the evidence base on NPS 
 
6.1.1. The speed of development and the proliferation of NPS represent a serious challenge in 
terms of the capacity of current systems of research and the technology available to 
government agencies.   The rate of growth in the number of new substances arriving in 
Britain;  the absence of a sound research infrastructure and resulting piecemeal 
organisation of research;  and limited access to technology are all impeding rational 
decision making.96 97 98 99 
6.1.2 When the ACMD can only make 2-3 recommendations to government per year concerning 
the risks associated with specific new psychoactive substances, it is important for them to 
know a) the preliminary evidence of the most harmful substances to work on;  and b) those 
substances taken by significant numbers of young people.  They don’t have this 
information. 
6.1.3. The Forensic Early Warning System (FEWS) with costs of at least £300,000 per annum only 
attempts to answer the basic, but challenging question of the composition of new drugs.  
The Advisory Council on the Misuse of Drugs includes leading international experts in the 
NPS field.    However, these scientists are working in a voluntary capacity.100 The research 
into the harmfulness of NPS and the prevalence of their use is largely undertaken by 
institutions where ACMD members are employed, funded by grants, some of short 
duration.  There is little guaranteed funding for research into NPS. 
6.1.4. According to ACMD and ICSD members, £3m per annum is required in order to provide a 
reasonable level of information for decision makers.  By contrast, the Home Secretary on 
17 May 2012 announced to the ACMD that £200,000 will be available for this work from 
the Department of Health101 . Potential ways to offset the costs associated with this 
research include the potential use of a University as a centre of excellence;  the 
development of existing networks;  and European pooling of resources. The basic 
identification of an unknown NPS can require a £600,000 high resolution gas or liquid 
chromatography mass spectrometer and a £1million nuclear magnetic resonance 
spectrometer.   For the Home Office’s FEWS these services are provided by a network of 
private forensic laboratories which can reduce costs by sharing expertise rather than all 
being involved in the most expensive stages of research.   Sharing the information 
regarding the NPS identified across Europe has reduced costs in the UK. Dr John Ramsey 
believes that use of University departments could reduce costs further as he believes they 
could carry out such work on a non-profit basis. 
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6.1.5 The National Programme on Substance Abuse Deaths (np-SAD) provided information about 
the contribution of drugs to deaths throughout the United Kingdom since 1997.   One 
project provided for the ACMD important data relating to the deaths of twenty six people, 
seeking to clarify whether mephedrone or other drugs had contributed to those deaths.   In 
August 2010 funding from the Department of Health for this research was ended.  Such 
data may not be available to the government or to ACMD in the future.  
6.1.6 The result of the inadequacies in the research infrastructure for NPS mean that decision 
makers have to rely upon studies of traditional drugs.  However, such an approach takes no 
account of the differences in the effect of drugs with apparently similar compositions. 
6.1.7 The weaknesses of the research infrastructure leave policy makers vulnerable. We do not 
know how many of the hundreds of substances identified since 1997 may be sufficiently 
harmful to justify the control of supply.   The ACMD will make 2 to 3 recommendations per 
year.  The rest remain uncontrolled.102    
6.1.8. What  research is needed to inform the decision makers on new psychoactive substances? 
The Independent Scientific Commission on Drugs  recommend a minimum data set 
composed of the following components: 
 Analyse products from test purchases, seizures and amnesty bins to find new 
compounds 
 Synthesise reference standards and possibly metabolites 
 Pharmacologically characterise the compound, in vitro and/or using isolated 
animal tissue models. This is required to establish whether and how a compound 
works as a drug and access the potency (dose). 
 Monitor any hospital Accident & Emergency presentations, and clinical 
assessments,  and confirm by urine analysis. 
 Access extent of use in the general population initially by pooled urine analysis 
(city centre urinals) and perhaps later by wastewater (sewage) analysis. 
 Repeat test purchases post legislation to monitor effectiveness103 
6.1.9 The identification of a single unknown NPS can cost between £300 and £10,000, but this is 
only the first stage of the minimum data set. The costs of this research are likely to be 
greater than the £300,000 per annum agreed for the identification process carried out by 
FEWS. The full minimum data would involve researchers from a broad range of 
departments.   This minimum data set does not account for the measurement of more long 
term toxicity and health effects. The longitudinal population research required to measure 
these harms would carry even greater costs and take longer. Dr John Ramsey advised that 
centralising this process in a centre of excellence in a university could reduce costs and 
avoid duplication. However, this model has not been fully developed or costed. 
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Recommendations 
6.1.10 All NPS should have their properties and prevalence assessed according to the basic data 
set recommended by the ISCD. Options for  this research should include the use of 
experts in university departments and pooling of European resources. 
6.1.11 All NPS policies should be evidence based and subject to evaluation. Such evaluations 
should seek to assess systems of regulation in terms of harms particularly harms to 
young people. A useful benchmark, operating within the New Zealand system, is that the 
harms of any form of regulation should  not be greater than the harms of the substance 
being regulated  
6.2 Access to Technology & Expertise 
6.2.1. In addition to the need to identify previously unknown NPS for research, Public Services, 
including the police and border enforcement (UKBA), probation (NOMS) and health 
services need access to sophisticated laboratory technology to identify packages and 
substances in human tissues. Clearly the needs of these services to identify drugs for the 
purposes of enforcement or treatment are different from the need to measure a minimum 
data set for all previously unknown NPS.   However, FEWS has demonstrated that these 
public services are the best sources for the samples of NPS needed for research. 
6.2.2 It might be hoped that these public services might be able to identify NPS themselves.   
However, current field technology is not fit for that purpose. According to Sheila Hardwick 
from the Home Office’s Centre for Applied Science & Technology the two forms of field 
technology used by SOCA and the UKBA cannot identify complex compounds and plant 
based drugs.   Similarly immunoassay urine drug tests used to identify drugs in hospital, 
probation and prison settings only test for a limited range of substances. 
6.2.3. Only forensic science and toxicology laboratories have access to sufficiently powerful 
technology and the skilled operators required to identify the drugs104.  These bring with 
them greater costs. Sheila Hardwick, who organised a network of forensic laboratories to 
identify previously unknown NPS through FEWS doubts that it would be realistic to expect 
the present NPS to be accurately identified by all the public services of the United 
Kingdom. The major limitation is the insufficient number of forensic scientists in the UK.   
Dr Ramsey was more optimistic and believed that the use of universities and students 
could increase the workforce for this task. Commercial quotes for identification of a known 
NPS can be around £40-104 per sample.  It is also possible that a sample from a public 
service contains an unknown NPS and these can naturally be fed into FEWS.  Dr Ramsey 
argues that these costs can be dramatically reduced through the involvement of 
universities and a non-profit model of NPS identification.  Identification of all NPS from 
these services would also be a rich source of information for researchers measuring 
patterns and quantity of both supply and use. 
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Keeping up with the Internet Vendors 
6.2.4. The widespread internet based sales of NPS and online social media forums discussing 
them highlight the importance of internet based technology.   SOCA has used specialist 
techniques to block unsafe vendors’ websites from the internet105.   Availability of these 
resources to other public services who take on any greater role in NPS management could 
enhance the possibility of controlling online sales to the UK.   However, blocking of 
websites is complex and costly.   Details about this are not in the public domain;  however 
an attempt to extend this technology to all enforcement agencies involved may be 
prohibitively expensive. There is the possibility of limiting such resources for the most 
irresponsible of vendors whilst cheaper and more basic interventions can address other 
internet suppliers. For example SOCA highlighted the value of simply asking internet 
providers to withhold access to the internet for vendors  who break their terms and 
conditions of use. 
Recommendation 
6.2.5. Access to technology and experts with the capacity to identify NPS should be available to 
all public services managing NPS use. In the case of technology addressing internet based 
sales, access to this technology should be limited to enforcement agencies and the most 
advanced technology may have to be reserved for the most problematic internet 
vendors. Measures to control costs should include the use of networks of experts. 
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7. Preventing and treating the  Misuse 
of NPS 
7.1 Prevention 
7.1.1 The Inquiry heard very little about drug education and prevention carried out specifically to 
address NPS. There is developing work by the Angelus Foundation and the Home Office 
managed ‘Talk to Frank’ website contains basic information about the more established 
NPS. In terms of drug use in general, drug education can potentially limit the amount of use 
and the dangerousness of use.  Evidence to this Inquiry emphasized the importance of 
prevention in any future drugs policy106 
7.1.2 The limited knowledge about the contents of,  and risks associated with, new psychoactive 
substances has inhibited the development of substance specific educational programmes.   
We have therefore explored the extent to which preventative programmes directed at the 
misuse of a range of substances including alcohol, tobacco and other drugs might be 
effectively applied to NPS.  Most of the trials have been conducted in the USA and have 
very little long-term follow up or investigation into the significance of the social context 
upon outcomes.    
7.1.3 Despite the caveats, the meta analysis of Pim Cuijpers, and other studies sited below have 
much to tell us about the potential of preventive interventions.107  Cuijpers refers to the 
several hundreds of studies and meta-analyses which have been conducted and the 
impossibility of undertaking a systematic review or meta-analysis covering the entire field.  
However, he does review the most important sections of the complete field 
7.1.4. According to Cuijpers, the aims of the programmes have varied;  they have included 
increasing knowledge about drugs;  reducing the use;  delaying the onset of first use;  
reducing abuse; and minimizing harm caused by use.  
7.1.5 Many of the programmes are interactive programmes.   They focus on discussions, role-
playing and interaction between students, while non-interactive programmes  are 
structured;  they focus on oral presentations by the teacher and do not stimulate 
interaction between students.   
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7.1.6. The main findings from all these studies have been a)  that programmes using interactive 
methods can significantly reduce the use of drugs (including tobacco, alcohol and illegal 
drugs); whereas non-interactive programmes do not;  b) programmes which focus upon 
parents and improve parenting skills of young people at risk can be effective; c) that 
community-based interventions providing activities for young people with the participation 
of residents can be effective; and   d) that the case for mass media campaigns is less clearly 
made out, but even if on their own these campaigns cannot reduce use, they may enhance 
the effectiveness of community interventions; 
7.1.7 The effects of interactive programmes upon drug use are small (0.20) but nevertheless 
significant if applied to large populations of young people.   Effective programmes are all 
based on the social-influence approach to drug prevention.   This is based upon the idea 
“that ‘inoculation’ in the classroom against active or indirect social pressure to use drugs 
will help to prevent drug use.”108  
7.1.8 Common sense suggests that selective or indicated interventions may be more effective 
than programmes directed at an entire cohort of children.  ‘ Selective’  interventions are 
aimed at individuals or groups of people who have an increased risk of drug use problems 
(e.g. children of alcoholics or high risk inner-city youngsters).   ‘Indicated’  prevention is 
aimed at subjects who do not have addiction problems but who have some early 
characteristics of problematic use. (young people already experimenting with drugs). 
7.1.9. Perhaps surprising is the conclusion from Cuijpers’ meta-analysis that “there is no 
convincing evidence that selective and indicated school-based prevention programmes can 
reduce drug use or abuse”.  
Family-based interventions 
7.1.10 It would be surprising if parents did not have an important part to play in reducing their 
children’s use and misuse of drugs.  But what does the research tell us about the influence 
of parents? 
7.1.11 Important protective characteristics of parents are a close relationship with their children 
and involvement of the parents in adolescent activities outside the family.109 Parents can 
also act as role models for their children.    
7.1.12. Can interventions in high risk families affect the drug use of adolescents?  An interesting 
study of the  effects upon 667 families  of the “Preparing for the Drug-free Years”  
programme  provides encouraging results.  Adolescents whose parents participated in the 
programme of just five training sessions, used fewer drugs than adolescents whose parents 
received a minimal intervention only.110  Other studies of interventions with families in 
which the parents are addicted,  or other high risk families, produced positive and 
significant effects on the drug use of the adolescents involved. 
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7.1.13. The only significant and relevant parenting programme in this country appears to have 
been the National Academy of Parenting Practitioners £30 million Department of 
Education project.   However, the impact of this work remains unknown. 
7.1.14. This field of study remains relatively new and further research is needed before the best 
interventions can be identified with full confidence. 
Mass Media Interventions 
7.1.15. Existing interventions include the website ‘Talk to Frank’ which provides  a degree of 
information about new psychoactive substances. The Angelus Foundation has recently 
mounted a billboard campaign against new psychoactive substances ( September 2012).   
7.1.16 However, there are no recent well-designed studies providing reliable assessments of the 
effectiveness of mass media campaigns on drug use.   The only conclusion drawn by 
Cuijpers is that mass media campaigns may strengthen the positive effects of community 
interventions. 
7.1.17 In the UK there have been a number of compelling campaigns about the dangers 
associated with the use of particular drugs such as ecstasy. But trends in the use of ecstasy 
do not appear to have been affected by such campaigns. 111   Mass campaigns can increase 
awareness about the availability of drugs without dissuading use.    
Community Interventions 
7.1.18 There are few studies of community projects – the organisation of activities aimed at 
`adolescents, as well as parents and others – on drug use.  However there is a growing 
evidence base to suggest that community prevention interventions can reduce drug use in 
the community.  More work needs to be done to strengthen the evidence in this area. 
 
Recommendations: 
7.1.19 Preventive programmes with a strong evidence base should be promoted much more 
widely within schools and the community.  
7.1.20 That resources are made available for robust evaluation in the UK of preventive 
programmes to assess their effectiveness in reducing the harms of NPS, delaying first use 
and to minimizing problematic use.  
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7.2 Treatment 
7.2.1. Evidence from the Department of Health and National Drug Treatment Agency suggests 
that General Practitioners and Accident and Emergency Departments treat a substantial 
proportion of acute harms arising from the taking of new psychoactive substances.112  We 
received little indication that the front line staff of health services have adapted their 
practice to meet the particular needs of young people suffering the harms resulting from 
NPS use, or that they are able to advise young people seeking help to reduce their use of 
these substances.113 We also have no information about the level of demand for NHS 
services from these groups. 
7.2.2. The Department of Health provided the Inquiry Panel with information about the general 
guidance issued to young people seeking health care but wishing to continue using NPS. 
This gave no specific information about the risks associated with any individual 
psychoactive substance. We have no information about the level of understanding of front 
line NHS staff of these substances.  The appearance of one new substance every six days or 
so into the UK and the minimal information available about each substance renders the 
position of health staff very difficult. 
7.2.3. Generic drug services, without specialist training and additional specialties (a bladder 
surgical specialist for example) are unlikely to be able to meet the needs of NPS users.114  
We know that ketamine and related NPS cause bladder damage.   These conditions will not 
be familiar to generic drug services. 
7.2.4. Because different NPS are popular in different parts of the Country, generating diverse 
health symptoms, the problems cannot be resolved on a national basis. 
Case study of health presentation of NPS user 
7.2.5 A Club Drug Clinic attender had taken ketamine and GHB and  attended with both bladder 
damage and physiological dependency.   Swift co-working with a bladder surgical specialist 
and an expert in the novel pharmacological detoxification involved was necessary.   The 
psychosocial treatments were adapted from those recommended by the National Institute 
for Health and Clinical Excellence, in guidance for all drug dependents. 
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7.2.6. Specialist Club Drug Clinics have begun to be established in several boroughs of London, in 
Bristol and in Leeds. With less high medication costs these services are often less expensive 
than other drug services.  The Chelsea & Westminster clinic costs £150,000 per annum. Dr 
Owen Bowden-Jones acknowledged that there may not be the demand for such clinics in 
every drug service across the United Kingdom, but predicted that a network of 5-10 clinics 
in major city hot spots across the country may help to meet this growing challenge. These 
hot spots may include Brighton, Bristol, several regions of London , Birmingham, 
Manchester, Leeds, Newcastle, Edinburgh and Glasgow.  The estimated cost of  5-10 such 
services would be between £750,000 to £1.5 million per year. He also advised that such 
clinics could provide  training for front line GP and A&E staff dealing with the acute effects 
of these drugs. These services might be more effectively commissioned at regional level or 
across several boroughs. 
Recommendation 
7.2.7 That a minimum of £1.5m be made available for a targeted pilot of Club Drug Clinics in 
ten major hot spots across the UK with a duty to train front line A&E and GP staff, as well 
as treat those suffering persistent harms of NPS use. 
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8. The Lead for Drug Policy 
8.1 The Home Office has been the lead department for drug policy since 1973. This followed 
logically from the passing of the 1971 Misuse of Drugs Act with its focus upon substance 
misuse as a problem of criminality rather than a health issue applying to users as well as 
suppliers.  However, prevention and treatment of drug addiction are now central to drug 
policy in the UK and will be equally important in the NPS field.   With the establishment of 
Public Health England and also if there is an enhanced role for regulation via Trading 
Standards Services then the Departments of Health and also  of Communities and Local 
Government will have an important role in the governance of drug policy. 
8.2. The UK is unusual in the European context in having the co-ordination of drug policy 
located within the Home Office rather than in the Health Department or divided between 
the two.115  However within Europe a health lead encompasses a considerable range of 
quality in drug policy and services. Having a particular government department in charge 
does not, in itself, guarantee an evidence based drugs policy.  
8.3. We have considered an analysis of the French system of governance in drugs policy 
involving a multi-departmental body under the leadership of the Prime Minister116.   A 
number of witnesses argued that the Health Department should be the coordinating 
Department.  This gives us options to consider. 
Recommendation:  
8.4 That the national governance of drug policy and the respective roles of the key 
departments  be incorporated into a review of the Misuse of Drugs Act (1971) already 
recommended   
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9. Appendix One: Current Regulation in 
the UK 
9.1 All products 
9.1.1 Revenue & Customs (HMRC) employ VAT, customs & excise, civil & civil evasion penalties or 
criminal proceedings including detention or seizing of goods and the containers or vehicles 
carrying them.117 
9.1.2 UK Border Agency customs checks carried out by the border force at ports and airports 
enable enforcement of the HMRC’s control of import of commodities.118 
9.1.3 Local Authority Trading Standards Officers enforce a wide range of legislation. They can 
utilise laws directly addressing the safety of goods, counterfeit goods and false claims on 
goods.119 
9.2 Hemp 
9.2.1 The Home Office Drugs Licensing Unit licenses cultivation and possession of Low or high THC 
industrial cannabis. CRB clearance of growers, field size & locations, seed type, THC content 
and a statement confirming EU approved seed status are all monitored.120 
9.2.2      Cultivators inform local police of their locations.121  
9.3 Alcohol 
9.3.1 The HMRC specifically tax the manufacturers, importers, distributors, retailers and 
consumers of certain alcohol products. 122 
9.3.2 Local authorities license individuals and premises to supply alcohol with conditions 
addressing prevention of crime and disorder, public safety, prevention of public nuisance 
and protection of children from harm. This now includes a minimum price that matches the 
VAT due for the drink. Failure to comply with any conditions attached to a licence or 
certificate is a criminal offence which on conviction would be punishable by a fine of up to 
£20,000 or up to six months imprisonment or both.123 
9.3.3  Local authorities, police and courts use drink banning orders to prevent alcohol use by 
antisocial and disorderly consumers. Offenders who breach a DBO will be liable to a fine of 
up to £2,500.124 
9.3.4. The police, CPS & courts can provide driving licence penalties, fines up to £5000 and up to 6 
months in prison for alcohol consumers who drink excessively and drive.125 
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9.4 Tobacco 
9.4.1. The HMRC only collects tobacco product duty from goods manufactured in registered 
factories, kept in registered stores and bearing a fiscal mark.  Other tobacco is seized, 
alongside any associated vehicles and the offenders’ assets are confiscated. Fines of up to 
£5,000 are given to owners of premises caught selling non-fiscally marked tobacco and the 
courts can ban their sale of tobacco for up to 6 months. Enforcement can require input from 
the trading standards officers, police, UKBA, CPS and Customs & Revenue Prosecutors, and 
the courts.126127 
9.4.2 Trading standards officers conduct test purchasing operations to detect deviation from retail 
regulations leading to criminal convictions, bans (restricted sales orders for individuals, 
restricted premises orders for establishments) and financial punishment (£1000-20,000). 
Retailers can only sell cigarettes in packets with mandatory health warnings, there must be a 
visible statutory notice of age requirements and consumers must be 18 or over.128 
9.4.3. Anyone detected by Trading Standards Officers to be involved in the commissioning, design, 
printing, publishing, sale or distribution of tobacco advertisement outside of retail outlets 
could face fines (starting at £3000) or imprisonment (starting at 6months).129 
9.4.4. Local authorities employ fixed penalty notices and fines from £50-2500 for individuals or 
managers of premises not displaying no smoking signs in work or public enclosed spaces.130 
9.4.5.     The NHS, schools & colleges educate people about the harms of smoking.131 
9.5 Gambling 
9.5.1        The HMRC have 6 specific taxes for gambling.132 
9.5.2 Licensing authorities are based in local authorities. They provide several licenses and 
registers for several aspects of gambling such as premises for gaming.133 
9.5.3. The Gambling Commission is a non-departmental public body sponsored by the 
department of culture, media and sport. It directly provides a number of licenses for 
gambling businesses who demonstrate efforts to reduce criminal involvement, protect the 
vulnerable and ensure fairness. The Commission, sometimes in conjunction with the police 
and CPS provide warnings, extra conditions, suspensions, revocation and fines.134 
9.5.4. The national lottery is regulated by the National Lottery Commission and spread betting is 
regulated by the Financial Services Authority.135 
9.6 Food 
9.6.1         The HMRC gather duty on some, but not all imported foods.136 
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9.6.2 Importers of animal derived food must acquire: a licence from DEFRA, a harmonised health 
certificate from a vet and details required to trace the product. 137   
9.6.3 Non-EU animal based products are: inspected by EU Border Inspection Posts including 
Official Veterinary Surgeons, Environmental Health Officers and specialist technical staff 
and  a Common Veterinary Entry Document (CVED), provided by a vet, is required. 138 
9.6.4 EU Importers of other food stuffs requirea licence from the Rural Payments Agency for 
import for food stuffs subject to the common agricultural policy.  Safety checks are carried 
out by environmental health officers. 139 
9.6.5 UK Food businesses undergoregistration with local authorities, food hygiene & safety 
inspections.  Investigations of specific complaints are carried out by the Food Standards 
Agency, the local authority (including port health authorities, food law enforcement 
Environmental Health Officers (EHOs) and Trading Standards Officers (TSOs). Breaking food 
laws can lead to fines and imprisonment from 6 months to 2 years. 140 
9.6.6. DEFRA’s Pesticides Safety Directorate (PSD), the Veterinary Medicines Directorate (VMD), 
and the Egg Marketing & Dairy Hygiene enforce specific monitoring and regulation of animal 
based food stuffs in the UK.141 
9.6.7. The Department of Health works in partnership with the food industry, charities, and other 
Government and non-governmental organisations to help the public choose healthier diets 
as part of a healthier lifestyle.142 
9.6.8. For TV advertising, OFCOM uses the nutrient profiling (NP) model as a tool to differentiate 
foods on the basis of their nutritional composition and restricts TV advertising of food and 
drink to children where products are high in fat, salt and sugar.143 
9.6.9.     NHS services provide interventions for people who are overweight.144 
9.7 Solvents 
9.7.1. Trading standards officers and the criminal justice system fine (up to £5000) or sentence (up 
to 6 months) retailers for selling solvents (eg; solvent based glue, dry cleaning fluid, 
correction fluid and thinner, marker pens, deodorant, air fresheners, hair spray, pain relief 
spray, anti-freeze & nail varnish and varnish remover) to people under 18 who are 
reasonably suspected of intending to use it for intoxication.145 
9.7.2. Any sale of butane to people under 18 leads to the same penalties without suspicion of 
intended intoxication.146 
9.8 Medicines 
9.8.1 The Medicines Health Regulatory Authority licenses new medicines on behalf of government 
ministers with guidance from the medical advisory committee at several stages.147  
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9.8.2. The MHRA’s Inspection Action Group review compliance at all points of the supply chain 
including clinical trials and testing of a medicine. They can remove licenses and refer people 
to the enforcement group. The Enforcement and Intelligence Group pursue convictions 
where people have deviated from the medicines act 1968.   They work with UK Police 
Forces, HM Revenue & Customs, Prescription Pricing Authority, Association of Port Health 
Officers, Trading standards and Environmental Health Units, Royal Pharmaceutical Society of 
Great Britain, General Medical Council and international authorities.148 
9.8.3. Medicines which require prescription (POM prescription only medicine) from a doctor 
require the involvement of both doctor and pharmacist. The General Medical Council and 
General Pharmaceutical Council can remove the individuals from their registers to prevent 
them supplying medicines unsafely. The GPhC also carries out inspections of registered 
pharmacy premises and can remove their licenses as well. Drugs also controlled under the 
MDA 1971 require further special prescription and dispensing measures.149150151 
9.8.4 Pharmacy only medicines do not require a prescription, but can only be dispensed by a 
registered pharmacy.152 
9.8.5      General sale medicines can be sold by general retailers.153 
9.8.6. Possession of prescription only medicines without a prescription is not an offence, if they are 
not also controlled by the MDA 1971. 
9.8.7. The Home Office Drugs Licensing and Compliance Unit (DLCU) annually license production, 
possession and supply of medicines and their precursors otherwise restricted by the Misuse 
of Drugs Act. Licenseescan be companies and other organisations that intend to work with 
controlled drugs and precursor chemicals, doctors prescribing certain drugs to addicts and 
people taking their prescribed controlled drugs abroad.  These licenses require:154 Criminal 
Records Bureau screening of licensees, demonstration of fulfilment of specific procedures 
addressing General Security Guidance for Controlled Drug Suppliers, production, 
distribution, storage, & provision to consumers, payment of substantial fees up to £4700, 
and occasional visits to check compliance. 
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10. Appendix Two: List of Expert 
Witnesses 
10.1  (Written Submissions only) 
Her Majesty’s Revenue & Customs, Sam Mitha, Deputy Director, Tax Policy  
Customs and National Operations, Border Force, Home Office, Tom Dowdall, Director  
Local Government Association, Councillor Mehboob Khan,  
Association of British Pharmaceutical Industry 
The Wine & Spirit Trade Association 
Department of Health 
10.2  (Oral Hearings & Written Submissions) 
Doctor Les King, Former member of the ACMD and advisor to the EMCDDA 
Rudi Fortson QC, Queen Mary University 
Advisory Council on the Misuse of Drugs, Professor Les Iversen  
Home Office, Gus Jaspert, Head of Drugs & Alcohol 
Trading Standards Institute, Craig McClue, South Ayrshire Trading Standards 
Medicines & Healthcare Products Regulatory Agency, Gerald W Heddell, Director, 
Inspection, Enforcement & Standards Division 
ACPO Drugs Committe, CC Tim Hollis, Chair  
Club Drug Clinic & Drug Treatment Centre, Dr Owen Bowden-Jones 
The Angelus Foundatio,  Maryon Stewart, Founder   
Professor Val Curran, University College London (ISCD) 
Dr Simon Elliot, Consultant Forensic Toxicologist and Managing Director of ROAR Forensics 
   Ltd in  Malvern, Worcestershire (ISCD) 
Dr Tim Williams, consultant addiction psychiatrist within the NHS and honorary clinical 
lecturer with  the University of Bristol (ISCD) 
John Ramsey, Director TICTAC Communications LTD 
Dr Fiona Measham, Lancaster University 
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10.3 (Oral Hearings Only) 
Kevin Costello, HMRC 
Mark Fuchter, UKBA 
Angelus Foundation, Jeremy Sare 
The Mentor Foundation Andrew Brown, Director of Programmes    
Department of Education, Christine Flower, Senior Policy Advisor on PSHE  
Department of Education, Jenny Loosley, Deputy Director for Curriculum and 
Disadvantaged Division 
Department for Education,  Paul Kissack, Director of Support and Delivery 
Department of Education,  Neil Dube, Young People Division  
Department of Education, Alison Hadley, Young People Division 
Serious Organised Crime Agency, Martin Malloy, Head of the Prevention Department  
Serious Organised Crime Agency, Lawrence Gibbons, Prevention Department,  
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11. Appendix three: Other Countries 
Responses to NPS 
 Apart from New Zealand which is covered in detail in the main body of the report, a 
number of countries have introduced legislation primarily to disrupt the supply of NPS. A 
selection of national initiatives is listed below. 
11.1 Ireland 
11.1.1. Under Ireland’s ‘Criminal Justice (Psychoactive Substances) Act 2010’, it is now  a criminal 
offence to advertise, sell or supply, for human consumption, psychoactive substances not 
specifically controlled under existing legislation. These are legally defined as substances 
which have the capacity to stimulate or depress the central nervous system, resulting in 
hallucinations, dependence or significant changes to motor function, thinking or behaviour. 
11.1.2. Those attempting to sell or supply such substances can be served  a ‘prohibition notice’. If 
they do not comply with this notice, the courts can issue a ‘prohibition order’. 
11.1.3. Selling, advertising and non-compliance with a ‘prohibition order’ are punishable by up to 
five years in prison. However, no offence or punishment is set out for the users of these 
substances. 
11.1.4. By adapting criminal justice legislation there is no requirement to harmonise specifically 
with EU directives.  
Impact of enforcement following the introduction of the legislation 
11.1.5. According to the national documentation centre for drug use in Ireland  ‘A Garda inventory 
of head shops in Ireland indicated that, at their peak in early 2010 there were 113 head 
shops in the country, with at least one in every county. On 11 May 2010 (the date of the 
government ban on a range of head shop products) there were 102 shops, 11 having 
closed for a variety of reasons. On 12 May, the gardaí visited all head shops and 
warehouses and seized all banned products. By 13 May there were 34 head shops selling 
psychoactive substances, and in early August the number increased to 39 shops. Following 
the introduction of the Criminal Justice (Psychoactive Substances) Act 2010, the gardaí 
visited head shops in early September.   Only 19 were open and none were selling 
psychoactive substances (Garda Síochána, personal communication, 2010).’155 
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Summary 
11.1.6.  The response of Ireland to NPS is to adapt their drugs legislation to capture any new 
substance that is judged to have a psychoactive effect and to put in place measures which 
prohibit the supply and sale of such substances. Whilst effective in curtailing head shops 
the impact on internet sales is unclear and there are likely to have been a number of 
displacement effects: 
 Head shop sales to internet sales 
 Sales in Ireland to sales in neighbouring countries 
 Sales of NPS to sales of established illegal drugs 
11.2 Poland 
11.2.1. In November 2010 a new law was  passed to limit the availability of ‘legal highs’. The new 
law amends two existing laws: 
11.2.2. The ‘Act on Counteracting Drug Addiction’, introducing a prohibition on the manufacture, 
advertising and introduction of ‘substitute drugs’. Substitute drugs are defined as a 
substance or plant used instead of, or for the same purposes as, a controlled drug, and 
whose manufacture or placing on the market is not regulated by separate provisions. 
11.2.3. The ‘Act on State Sanitary Inspection’.   This adds to the powers of state sanitary inspectors  
to act against any ‘failure to meet hygiene and health requirements’ a power to withdraw 
from trade a ‘substitute drug’ for up to 18 months in order to assess its safety, if there is a 
justified suspicion that it might pose a threat to life or health. The costs of the assessment 
are met by the distributor in the event that the drug is harmful. If the drug is found to be 
harmless, the cost will be reimbursed by the state. The inspectors also have the right to 
close premises for up to three months.156  
11.3 Sweden 
11.3.1. On April 1st 2011 Sweden introduced the ‘Destruction Act’. The Act is linked to existing 
legislation – the Narcotic Drugs Control Act (1992) and the Act on the Prohibition of certain 
Goods Dangerous to Health (1999). Substances can be seized and destroyed under the 
following conditions: 
 a substance has been declared as psychoactive or hazardous to health but has not yet 
been made subject to drug control legislation; 
 a substance has been internationally declared as being subject to UN Drug Conventions 
but the decision has not yet come into force; 
 it is presumed that the substance will become regulated as a narcotic substance of 
abuse or hazardous to health by the Swedish Government157 
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11.3.2. According to the Swedish National Institute of Public Health, the Swedish Police and 
Customs Service made almost 1100 seizures of incoming mail concerning new psychoactive 
substances in 2011 using these powers.  
11.4 Austria 
11.4.1. Austria introduced the  ‘Act on new psychoactive substances’ on 1 January 2012. According 
to the EMCDDA ‘This act controls substances listed in a regulation by the Minister for 
Health, which are not subject to the 1961 or 1971 UN drug conventions. Substances are 
only listed in the regulation if they have the potential for ‘psychoactive effects’ (on the 
human central nervous system, such as hallucinations or disturbances in motor functions, 
perception, behaviour). Listed substances are also likely to be abused by certain sections of 
society and pose a potential threat to consumer health. 
11.4.2. Unauthorised supply is considered a crime if the supplier aims to benefit and intends that 
the product be used for its psychoactive effects ..... (and) ...  seizure of any amount of 
substance is possible even when there is no suspicion of supply.’158 
11.5 Hungary 
11.5.1. According to the EMCDDA Hungary introduced Government Decree 66/2012 on the 3rd 
April which added a Schedule C to existing legislation listing drugs appearing on the 
market. To be included on the schedule, the substance will have undergone a  rapid 
assessment and meet two criteria: 
11.5.2 the substance can affect the central nervous system, and is understood to pose as serious a 
threat to public health as the substances listed in the drug conventions and;the substance 
has no therapeutic use.  
11.5.3 Within one year of being placed on Schedule C, the drug must be risk-assessed, resulting in 
full drug control or removal from the schedule. However, generic groups of substances will 
remain on the schedule as long as any substance in the group fulfils the above 
requirements. ‘A new section of the Criminal Code (s.283/B) states that offering or 
Distribution, but not possession, of such substances is punishable by up to three years in 
prison.’159 
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12. Appendix four: Glossary 
ACMD Advisory Committee on the Misuse of Drugs 
ACPO Association of Chief Police Officers 
BCS  British Crime Survey 
BZP  Benzylpiperazine 
CAST Centre for Applied Science & Technology 
CRB  Criminal Records Bureau 
DBO  Drink Banning Order 
DLCU Home Office Drugs Licensing and Compliance Unit 
DEFRA Department for Environment, Food and Rural Affairs 
EMCDDA European Monitoring Centre for Drugs and Drug Abuse 
FEWS Forensic Early Warning System 
GHB  gamma-hydroxy-butyrate  
ISCD  Independent Scientific Committee on Drugs 
LGA  Local Government Agency 
MDMA Methylenedioxymethamphetamine 
NICE National Institute for Health and Clinical Excellence 
NOMS National Offender Mangement Service 
NPS   Novel Psychoactive Substances 
np-SAD  National Programme on Substance Abuse Deaths  
PSHE Personal, Social and Health Education 
SOCA Serious Organised Crime Agency 
TCDO Temporary Class Drug Order 
THC  Tetrahydrocannabinol 
TSS  Trading Standards Services 
TSI  Trading Standards Institute 
UKBA United Kingdom Border Agency / Force 
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